The Future Looks bRIGHT for Tricuspid Valve Repair

Amanda Pedersen | May 18, 2023

Late-breaking data presented at EuroPCR in Paris, France this week supports the benefits of Abbott's TriClip transcatheter edge-to-edge repair (TEER) system in treating patients with leaky tricuspid valves. The Abbott Park, IL-based company said the TriClip device is a first-of-its kind, minimally invasive device designed specifically for tricuspid heart valve repair.

The results of the bRIGHT study, the largest real-world dataset for transcatheter tricuspid valve repair, support the safety and effectiveness of the TriClip system in patients with tricuspid regurgitation (TR). Outcomes from 511 patients in 26 sites across Europe for this prospective, multi-center, single-arm post-market study were presented for the first time at EuroPCR 2023.

Abbott's TriClip transcatheter edge-to-edge repair (TEER) system is investigational only in the United States.

"Many patients currently undergoing tricuspid TEER are at an advanced stage of the TR disease and experience severe symptoms, impacting their overall health and well-being," said Philipp Lurz, MD, PhD, professor and deputy head of cardiology at the Heart Center Leipzig at University of Leipzig, in Leipzig, Germany. "Building strong clinical evidence around the value of a procedure like tricuspid valve repair is critical, and the real-world outcomes of the bRIGHT study reinforce the safety and effectiveness of TriClip in reducing TR and improving quality of life."

TriClip is approved for use in more than 50 countries, including in Europe and Canada, and is an investigational device in the United States.

More information about text formats

Search qualified tubing and extrusion suppliers on the Qmed Directory, the world's only directory of pre-qualified suppliers to the medical device and diagnostics industry.